PURPOSE: For more than half a century, researchers have explored myeloablative, high-dose chemo/radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HCT) for therapy of malignant and nonmalignant hematological diseases. Continuous advances in the field have changed this approach from one that was initially thought to be fraught by insurmountable complications to one that is now considered standard therapy for many diseases. METHODS: In order to extend allogeneic HCT to include elderly patients, who represent the main population affected by hematological malignancies, and to those who are medically unfit to undergo conventional HCT, novel non-myeloablative approaches have been developed. These approaches rely on graft-vs-tumor effects for tumor eradication rather than high-dose chemoradiotherapy, and, accordingly, have lower toxicities than conventional regimens. RESULTS: Results with non-myeloablative regimens have been gratifying, and this may change the future of allogeneic HCT. Advances could not have been possible without basic research and studies in pre-clinical animal models. CONCLUSION: Further work is focused on improving graft-vs-tumor effects while achieving better control of graft-vs-host disease.
PURPOSE: For more than half a century, researchers have explored myeloablative, high-dose chemo/radiotherapy followed by allogeneic hematopoietic stem cell transplantation (HCT) for therapy of malignant and nonmalignant hematological diseases. Continuous advances in the field have changed this approach from one that was initially thought to be fraught by insurmountable complications to one that is now considered standard therapy for many diseases. METHODS: In order to extend allogeneic HCT to include elderly patients, who represent the main population affected by hematological malignancies, and to those who are medically unfit to undergo conventional HCT, novel non-myeloablative approaches have been developed. These approaches rely on graft-vs-tumor effects for tumor eradication rather than high-dose chemoradiotherapy, and, accordingly, have lower toxicities than conventional regimens. RESULTS: Results with non-myeloablative regimens have been gratifying, and this may change the future of allogeneic HCT. Advances could not have been possible without basic research and studies in pre-clinical animal models. CONCLUSION: Further work is focused on improving graft-vs-tumor effects while achieving better control of graft-vs-host disease.
Authors: E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner Journal: N Engl J Med Date: 1975-04-17 Impact factor: 91.245
Authors: E D Thomas; C D Buckner; R A Clift; A Fefer; F L Johnson; P E Neiman; G E Sale; J E Sanders; J W Singer; H Shulman; R Storb; P L Weiden Journal: N Engl J Med Date: 1979-09-13 Impact factor: 91.245
Authors: J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave Journal: Ann Intern Med Date: 1988-06 Impact factor: 25.391
Authors: E D Thomas; R A Clift; J Hersman; J E Sanders; P Stewart; C D Buckner; A Fefer; R McGuffin; J W Smith; R Storb Journal: Int J Radiat Oncol Biol Phys Date: 1982-05 Impact factor: 7.038
Authors: E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden Journal: Blood Date: 1977-04 Impact factor: 22.113
Authors: Marco Mielcarek; Paul J Martin; Wendy Leisenring; Mary E D Flowers; David G Maloney; Brenda M Sandmaier; Michael B Maris; Rainer Storb Journal: Blood Date: 2003-03-27 Impact factor: 22.113
Authors: M Bornhäuser; U Schuler; G Pörksen; R Naumann; G Geissler; C Thiede; R Schwerdtfeger; G Ehninger; H M Thiede Journal: Transplantation Date: 1999-02-27 Impact factor: 4.939
Authors: N Schmitz; A Bacigalupo; D Hasenclever; A Nagler; E Gluckman; P Clark; P Bourquelot; H Greinix; N Frickhofen; O Ringdén; A Zander; J F Apperley; C Gorin; K Borkett; G Schwab; M Goebel; N H Russell; A Gratwohl Journal: Bone Marrow Transplant Date: 1998-05 Impact factor: 5.483
Authors: William H Peranteau; Todd E Heaton; Yu-Chen Gu; Susan W Volk; Thomas R Bauer; Keith Alcorn; Laura M Tuschong; Mark P Johnson; Dennis D Hickstein; Alan W Flake Journal: Biol Blood Marrow Transplant Date: 2009-03 Impact factor: 5.742